BUDESONIDE

Information current as at: 1 July 2026

PBAC meeting date: November 2026
Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Jorveza®
Form and strength:
  • Oral suspension 0.2 mg per 1 mL, 165 mL
Submission sponsor:
DR FALK PHARMA AUSTRALIA PTY LTD
Condition/indication:
(therapeutic use)
  • Eosinophilic oesophagitis
Listing requested:
To request a new oral suspension form of budesonide (BOS) for the treatment of patients with eosinophilic oesophagitis. The proposed restrictions for BOS are based on those for budesonide orally disintegrating tablet (BOT) but with a number of changes, some of which are requested to flow on to BOT. One such change is the removal of the requirement for a biopsy / histologic assessment within 12 weeks of applying for treatment.
Funding program:
PBS General Schedule
Request authority level:
Authority Required (STREAMLINED)
PBAC Submission type:
New PBS listing (–)
Comment:
--
Other PBAC consideration:
--

Progress Details

Submission received for:
November 2026 PBAC meeting
2Opportunity for consumer comment:
Open 22/07/2026 and close 16/09/2026 (see PBS Website)
3PBAC meeting:
Has not yet occurred
4PBAC outcome published:
Pending PBAC outcome (see PBAC Outcomes)
5Lodgement of required documentation:
6Agreement to listing arrangements:
Has not yet commenced
7Government processes:
Has not yet commenced
8Medicine listed on the PBS:
Has not yet occurred
Glossary

PBAC Outcome

PBAC Recommendation:
Please see the Outcomes from the relevant meeting for more information
Case ID
a1268
Page last updated
23 July 2026
Return to the Medicine Status Listing
v.9.19